Abstract
A combination of the anti-human epidermal growth factor receptor 2 (HER2) monoclonal antibodies pertuzumab (Genentech) and trastuzumab (Herceptin; Genentech) with docetaxel has reduced risk of progression by 38% over treatment with trastuzumab and docetaxel in a study of 808 patients with HER2-positive metastatic breast cancer.
This content is only available via PDF.
©2011 American Association for Cancer Research.
2011